New combo aims to boost immune attack on liver tumors after radiation
Disease control
Recruiting now
This phase II trial tests whether giving immune-boosting drugs (durvalumab with or without tremelimumab) after standard radiation can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation f…
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC